The EPA-registered disinfectant products on our Disinfectants for Use Against SARS-CoV-2 list have qualified under EPA’s emerging viral pathogen program for use against SARS-CoV-2, a coronavirus that causes COVID-19. Coronaviruses are enveloped viruses, meaning they are one of the easiest types of viruses to kill with the appropriate disinfectant product. The emerging viral pathogen guidance was triggered for SARS-CoV-2 on January 29, 2020.
EPA strongly recommends following the product label use directions for enveloped viruses, as indicated by the approved emerging viral pathogen claim on the master label. If the directions for use for viruses/virucidal activity list different contact times or dilutions, use the longest contact time or most concentrated solution.
Application Information for Registrants Wanting an Emerging Viral Pathogen Claim
A company can apply for an emerging viral pathogens claim, even before an outbreak occurs, based on previously EPA-approved claims for harder-to-kill viruses. EPA reviews the supporting information and determines if the claim is acceptable. Once approved, a company can make certain off-label claims as specified in the policy in the event of an outbreak such as the SARS-CoV-2. For instance, the company can include an efficacy statement on:
- technical literature distributed to health care facilities, physicians, nurses, public health officials;
- non-label-related websites;
- consumer information services; and
- social media sites.
Companies with EPA-registered disinfectants that want their products added to List N, should provide the information as outlined below to disinfectantslist (disinfectantslist@epa.gov).
- Ensure that the product has a previously approved emerging viral pathogen claim.
- Provide the product name and EPA Registration number.
Note: There may be additional disinfectants that meet the criteria for use against SARS-CoV-2. EPA will update this list with additional products as needed.
Source: https://www.epa.gov/pesticide-registration/list-n-disinfectants-use-against-sars-cov-2
